000281833 001__ 281833
000281833 005__ 20251218103439.0
000281833 0247_ $$2doi$$a10.1111/jnc.70263
000281833 0247_ $$2pmid$$apmid:41147537
000281833 0247_ $$2ISSN$$a0022-3042
000281833 0247_ $$2ISSN$$a1471-4159
000281833 037__ $$aDZNE-2025-01214
000281833 041__ $$aEnglish
000281833 082__ $$a610
000281833 1001_ $$0P:(DE-HGF)0$$aFernandez Flores, Leticia Camila$$b0$$eFirst author
000281833 245__ $$aMultiple Antibody-Coated Gold Nanoparticle-Based ExoAssay for Rapid Isolation of CNS-Specific Exosomes From Blood.
000281833 260__ $$aOxford$$bWiley-Blackwell$$c2025
000281833 3367_ $$2DRIVER$$aarticle
000281833 3367_ $$2DataCite$$aOutput Types/Journal article
000281833 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761742838_30626
000281833 3367_ $$2BibTeX$$aARTICLE
000281833 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281833 3367_ $$00$$2EndNote$$aJournal Article
000281833 520__ $$aIn neurodegenerative diseases, brain-derived extracellular vesicles (EVs)/exosomes from blood offer a great opportunity to explore their contents for their utility as biomarkers. However, the conventional methodologies for the purification of EVs from complex biofluids have many limitations, restricting their clinical implementation. We aimed to optimize a direct, less time-consuming, affordable, and reliable nanowire-based method to isolate neuronal EVs from blood plasma. Here, we improved a simple and direct methodology using multiple antibody-coated magnetic nanowires for efficient and rapid isolation of neuronal EVs (ExoAssay) from human plasma. We characterized the isolated EVs and validated the protocol using multiple approaches, for example, nanoparticle tracking analysis (NTA), immunoblotting, and transmission electron microscopy (TEM). We purified round-shaped EVs with an average size of 116 nm. We identified the general markers of EVs including CD9, CD63, CD81, and Flotillin-1 and two neuronal EV markers L1-cell adhesion molecule (L1CAM) and neural cell adhesion molecule (NCAM) via immunoblotting. Interestingly, the levels of T-Tau and P-Tau were upregulated in EVs isolated from Alzheimer's patients (n = 30), in comparison with healthy controls. Furthermore, there were no significant differences between CSF- and EV-based Tau levels. The high-throughput mass-spectrometry analysis of isolated EVs revealed 280 proteins as significantly modified in Alzheimer's disease cases in comparison with controls. The presented nanotechnology-based methodology offers an innovative and efficient tool for EV-based biomarker investigations and clinical utility by simplifying the enrichment of CNS-originated exosomes from complex biological fluids. This methodology opens up the avenue for longitudinal monitoring of important disease-related proteins in the brain by analysis of brain-derived EVs from blood plasma using simple blood withdrawal.
000281833 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281833 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281833 650_7 $$2Other$$aAlzheimer's disease
000281833 650_7 $$2Other$$aExoAssay
000281833 650_7 $$2Other$$abiomarkers
000281833 650_7 $$2Other$$aneuronal EVs
000281833 650_7 $$2Other$$aplasma
000281833 650_7 $$2Other$$atau
000281833 7001_ $$0P:(DE-2719)9001558$$aYounas, Neelam$$b1
000281833 7001_ $$aGoebel, Stefan$$b2
000281833 7001_ $$aDittmar, Kathrin$$b3
000281833 7001_ $$0P:(DE-2719)9003742$$aSaleem, Tayyaba$$b4$$udzne
000281833 7001_ $$0P:(DE-2719)9003090$$aYounas, Abrar$$b5$$udzne
000281833 7001_ $$aBudde, Holger$$b6
000281833 7001_ $$aLegler, Tobias J$$b7
000281833 7001_ $$aMöbius, Wiebke$$b8
000281833 7001_ $$aHermann, Peter$$b9
000281833 7001_ $$0P:(DE-2719)9000287$$aSchmitz, Matthias$$b10$$udzne
000281833 7001_ $$0P:(DE-2719)2000058$$aZerr, Inga$$b11$$eLast author$$udzne
000281833 773__ $$0PERI:(DE-600)2020528-4$$a10.1111/jnc.70263$$gVol. 169, no. 10, p. e70263$$n10$$pe70263$$tJournal of neurochemistry$$v169$$x0022-3042$$y2025
000281833 8564_ $$uhttps://pub.dzne.de/record/281833/files/DZNE-2025-01214.pdf$$yOpenAccess
000281833 8564_ $$uhttps://pub.dzne.de/record/281833/files/DZNE-2025-01214.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281833 909CO $$ooai:pub.dzne.de:281833$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000281833 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000281833 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001558$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000281833 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003742$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000281833 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003090$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000281833 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000287$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000281833 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000058$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000281833 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281833 9141_ $$y2025
000281833 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROCHEM : 2022$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-01$$wger
000281833 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281833 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-01
000281833 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000281833 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281833 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-01$$wger
000281833 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000281833 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarker$$x0
000281833 980__ $$ajournal
000281833 980__ $$aVDB
000281833 980__ $$aUNRESTRICTED
000281833 980__ $$aI:(DE-2719)1440011-1
000281833 9801_ $$aFullTexts